Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genom-wide expression study of cMoP and iMoP from murine bone marrow

ABSTRACT: We defined iMoP as a new precursor subset in murine bone marrow. The aim of this expression analysis was the identification of transcriptional differences between iMoP and their progeny cMoP.

ORGANISM(S): Mus musculus

PROVIDER: GSE117460 | GEO | 2021/01/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genom-wide expression study of cMoP and monocytes from murine bone marrow compared to their differentiated descendants

Project description:cMoP and monocytes differ in their potential to form multinucleated giant cells (MGC) in reaction to mycobacterial ligands. The aim of this expression analysis was the identification of transcriptional differences undelying the mechanisms of MGC formation.

2021-01-04 | GSE117456 | GEO

Genom-wide expression study of cMoP and iMoP from murine bone marrow

Project description:Genom-wide expression study of cMoP and iMoP from murine bone marrow

| PRJNA482151 | ENA

RNAseq transcriptome analysis reveals developmental heterogeneity among mouse bone marrow monocyte subsets

Project description:Purpose: In our study, we identified a heterogeneity among bone marrow (BM) Ly6Chi monocytes, which can be subdivided the expression of CXCR4. In order to understand the development of BM monocytes, the goal of this experiment is to compare the transcriptome of these 2 BM Ly6Chi monocyte subsets to those of the common monocyte progenitor (cMoP) and Ly6Clo monocytes.

2016-09-29 | GSE86079 | GEO

Genom-wide expression study of cMoP and monocytes from murine bone marrow compared to their differentiated descendants

Project description:Genom-wide expression study of cMoP and monocytes from murine bone marrow compared to their differentiated descendants

| PRJNA482147 | ENA

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Project description:RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.

| 2004880 | ecrin-mdr-crc

scRNA-seq to study features of CD4conv and Treg cells in spleen and bone marrow of mice

Project description:The aim of the study was to compare gene experession between Treg cells in the bone marrow and the spleen

2022-05-16 | GSE202888 | GEO

Bone marrow niche

Project description:Bone marrow niche

| PRJNA429031 | ENA

Identifying bone marrow microenvironmental alterations in multiple myeloma and its precursor conditions using whole bone marrow biopsies

Project description:Identifying bone marrow microenvironmental alterations in multiple myeloma and its precursor conditions using whole bone marrow biopsies

| PRJNA1157850 | ENA

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Project description:This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with high-risk hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells by stopping them from dividing or killing them. Giving cyclophosphamide after transplant may also stop the patient’s immune system from rejecting the donor’s bone marrow stem cells. The donated stem cells may replace the patient’s immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body’s normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening

| 2008483 | ecrin-mdr-crc

microRNA profiling of multiple myeloma bone marrow

Project description:Bone marrow microenvironment in MM contains a unique miR signature, which is partially present and detectable in the peripheral blood. A subset of miRs (let-7i, miR-106b, miR-15a, and miR16) shows aberrant expression in the precursor lesion of MGUS, while aberrant expression of other miRs (let-7a, miR-15a/b, miR-19b, miR-20a, miR-21, miR-223, and miR-361) is associated with cell proliferation and disease progression. miRNA profiling was performed using Agilent miRNA array platforms with RNAs isolated from the bone marrow supernatant of multiple myeloma.

2016-07-01 | E-GEOD-49261 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data